Chocolate elicits unique brain activity compared to other foods, activating similar brain regions and neurobiological substrates with potentially similar psychoactive effects as substances of abuse. We sought to determine the relationship between chocolate with varying combinations of its main constituents (sugar, cocoa, and fat) and its psychoactive effects. Participants consumed 5 g of a commercially available chocolate with increasing amounts of sugar (90% cocoa, 85% cocoa, 70% cocoa, and milk chocolates). After each chocolate sample, participants completed the Psychoactive Effects Questionnaire (PEQ). The PEQ consists of questions taken from the Morphine-Benzedrine Group (MBG), Morphine (M,) and Excitement (E) subscales of the Addiction Research Center Inventory. After all testing procedures, participants completed the Binge Eating Scale (BES) while left alone and allowed to eat as much as they wanted of each of the different chocolates. We found a measurable psychoactive dose⁻effect relationship with each incremental increase in the chocolate's sugar content. The total number of positive responses and the number of positive responses on the E subscale began increasing after tasting the 90% cocoa chocolate, whereas the number of positive responses on the MBG and M subscales began increasing after tasting the 85% cocoa chocolate sample. We did not find a correlation between BES scores and the total amount of chocolate consumed or self-reported scores on the PEQ. These results suggest that each incremental increase in chocolate's sugar content enhances its psychoactive effects. These results extend our understanding of chocolate's appeal and unique ability to prompt an addictive-like eating response.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471517 | PMC |
http://dx.doi.org/10.3390/nu11030596 | DOI Listing |
Dis Mon
January 2025
NYU Grossman School of Medicine, Department of Population Health, New York, NY, USA.
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and diaphoresis. Post-intoxication phenomena may include insomnia, anhedonia, anxiety, depression, and memory impairment, which can persist for days following drug cessation.
View Article and Find Full Text PDFACS Med Chem Lett
January 2025
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
Recent advancements in pharmaceutical research have focused on developing novel psychoactive compounds and receptor modulators that enhance therapeutic outcomes while minimizing adverse effects. This Patent Highlight examines three innovative approaches: (1) transmucosal delivery of dephosphorylated psychoactive alkaloids, (2) nonhallucinogenic serotonin receptor modulators, and (3) ergoline analogues designed for treating neurological disorders. These innovations offer breakthroughs in drug delivery, receptor targeting, and structural modifications, aiming to address challenges in the treatment of mood disorders, neurological diseases, and chronic pain while improving bioavailability and reducing side effects and hallucinogenic properties.
View Article and Find Full Text PDFCurr Neuropharmacol
January 2025
Department of Neurosciences 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Introduction/objective: Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups.
Methods: This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study).
Basic Clin Pharmacol Toxicol
February 2025
Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating studies of the latter. Up to 138 NPS were retrospectively identified using liquid chromatography-high resolution mass spectrometry data from all 34 183 oral fluid drug samples collected in one Swedish health care region 2019-2020 representing 9468 psychiatric and addiction care patients. In total, 618 findings representing 58 NPS were detected in 481 samples from 201 patients.
View Article and Find Full Text PDFClin Neuropharmacol
January 2025
Eastern Virginia Medical School, Norfolk, VA.
Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.
Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!